Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866177 · ClinicalTrials.gov registry record · Phase 2
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00866177: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00866177 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 167 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00866177, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Anti-tumor response defined as either a Complete Response, Partial Response, or Stable Disease as defined by RECIST
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT00866177 record still lists
NCT00866177 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00866177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00866177 about?
NCT00866177 is a clinical study titled "MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma". This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00866177?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2009-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00866177?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Selumetinib (DRUG).
Who is sponsoring clinical trial NCT00866177?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00866177's enrollment target sits among peer trials
167 406th of 2000 higher than 1,595 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia